Pharma IQ has conducted an interview with Chrissie Fletcher, Director and Head of International Biostatistics at Amgen, about Health Technology Assessment. Fletcher said: "The Health Technology Assessment dossier is really the single opportunity that people have to convince payers of the value of a new product coming through. So in order to do that effectively, the more that that data is available for that dossier, and it's reported in the right way, means that you're going to have your best chance. And it should be as comprehensive and as transparent and as unbiased as possible... 
More...
More...